WITH IDELVION, UP TO 14-DAY DOSING GIVES PATIENTS GREATER FREEDOM FROM INFUSIONS

Only IDELVION is FDA approved for up to 14-day dosing in patients 12 years and older

Choose the regimen that's right for your patients and adjust based on their clinical condition and response.

7-day dosing regimen for IDELVION | 14-day dosing regimen for IDELVION 7-day dosing regimen for IDELVION | 14-day dosing regimen for IDELVION

*In the clinical trials, well-controlled was defined as 1 month without spontaneous bleeding on a weekly dose of ≤40 IU/kg.

Flexibility to meet your patients' needs—from 250 IU to 3500 IU

5 vial sizes for optimal flexibility and efficiency.

  • A range of sizes to facilitate the regimen you choose
  • Reconstituting is fast and simple using the Mix2Vial® needle-free reconstitution and transfer system
IDELVION 250 IU vial size for dosing flexibility
250 IU

KIT NDC:

69911-864-02

2.5-mL diluent

IDELVION 500 IU vial size for dosing flexibility
500 IU

KIT NDC:

69911-865-02

2.5-mL diluent

IDELVION 1000 IU vial size for dosing flexibility
1000 IU

KIT NDC:

69911-866-02

2.5-mL diluent

IDELVION 2000 IU vial size for dosing flexibility
2000 IU

KIT NDC:

69911-867-02

5-mL diluent

IDELVION 3500 IU vial size for dosing flexibility
3500 IU

KIT NDC:

69911-869-02

5-mL diluent

Images are representations, not actual depictions of actual vials.

No refrigeration of IDELVION required:

  • Store IDELVION package in the refrigerator or at room temperature 36°F–77°F (2°C–25°C). Do not freeze
  • Do not store past expiration date printed on carton or vial

  Mix2Vial® is a registered trademark of West Pharma. Services IL, Ltd., a subsidiary of West Pharmaceuticals Services, Inc.

Dosing for on-demand treatment

Dosing for perioperative management

Dosing for on-demand treatment

Type of Bleeding Episode
MINOR OR MODERATE Uncomplicated hemarthrosis, muscle bleeding (except iliopsoas) or oral bleeding
MAJOR Life or limb threatening hemorrhage, deep muscle bleeding, including iliopsoas, intracranial, retropharyngeal
Circulating Factor IX Activity Required [% or (IU/dL)]
30–60
60–100
Frequency of Dosing (hours)
48–72
48–72
Duration of Therapy (days)
At least 1 day, until bleeding stops and healing is achieved. Single dose should be sufficient for majority of bleeds
7–14 days, until bleeding stops and healing is achieved. Maintenance dose weekly

Dosing for perioperative treatment

Type of Surgery
MINOR (including uncomplicated tooth extraction)
MAJOR (including intracranial, pharyngeal, retropharyngeal, retroperitoneal)
Circulating Factor IX Activity Required [% or (IU/dL)]
50–80
60–100 (initial level)
Frequency of Dosing (hours)
48–72
48–72
Duration of Therapy (days)
At least 1 day, or until healing is achieved. Single dose should be sufficient for majority of minor surgeries.
7–14 days, or until bleeding stops and healing is achieved. Repeat dose every 48–72 hours for the first week or until healing is achieved. Maintenance dose 1–2 times per week.

†Adapted from the WFH Guidelines for the Management of Hemophilia.

IDELVION has ZERO median annualized spontaneous bleeds in prophylaxis

VIEW EFFICACY DATA
You are now leaving the current website.

Do you want to continue?

No Yes